Mycenax Biotech Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 106.733 million compared to TWD 268.972 million a year ago. Operating loss was TWD 64.669 million compared to operating Income of TWD 82.167 million a year ago. Net loss was TWD 69.102 million compared to net income of TWD 78.648 million a year ago. Basic loss per share from continuing operations was TWD 0.45 compared to basic earnings per share from continuing operations of TWD 0.62 a year ago. For the half year, sales was TWD 398.950 million compared to TWD 338.833 million a year ago. Operating income was TWD 50.009 million compared to TWD 56.244 million a year ago. Net income was TWD 45.284 million compared to TWD 57.045 million a year ago. Basic earnings per share from continuing operations was TWD 0.32 compared to TWD 0.45 a year ago. Diluted earnings per share from continuing operations was TWD 0.31 compared to TWD 0.45 a year ago.